Literature DB >> 25791078

Western European markets for biosimilar and generic drugs: worth differentiating.

Livio Garattini1, Alessandro Curto, Katelijne van de Vooren.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25791078     DOI： 10.1007/s10198-015-0684-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  19 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.

Authors:  Menno van Woerkom; Hans Piepenbrink; Brian Godman; Joost de Metz; Stephen Campbell; Marion Bennie; Marietta Eimers; Lars L Gustafsson
Journal:  J Comp Eff Res       Date:  2012-11       Impact factor: 1.744

3.  Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?

Authors:  Pieter Dylst; Arnold Vulto; Steven Simoens
Journal:  Health Policy       Date:  2011-04-21       Impact factor: 2.980

Review 4.  Regulatory and clinical considerations for biosimilar oncology drugs.

Authors:  Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

5.  The economics of biosimilars.

Authors:  Erwin A Blackstone; P Fuhr Joseph
Journal:  Am Health Drug Benefits       Date:  2013-09

Review 6.  The role of biosimilars in the treatment of rheumatic diseases.

Authors:  Thomas Dörner; Vibeke Strand; Gilberto Castañeda-Hernández; Gianfranco Ferraccioli; John D Isaacs; Tore K Kvien; Emilio Martin-Mola; Thomas Mittendorf; Josef S Smolen; Gerd R Burmester
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

Review 7.  Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review.

Authors:  Mohamed Azmi Hassali; Zhi Yen Wong; Alian A Alrasheedy; Fahad Saleem; Abdul Haniff Mohamad Yahaya; Hisham Aljadhey
Journal:  Health Policy       Date:  2014-08-01       Impact factor: 2.980

8.  Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.

Authors:  Sandro Curto; Simone Ghislandi; Katelijne van de Vooren; Silvy Duranti; Livio Garattini
Journal:  Health Policy       Date:  2014-02-17       Impact factor: 2.980

9.  Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?

Authors:  Livio Garattini; Katelijne van de Vooren; Alessandro Curto
Journal:  Health Policy       Date:  2014-12-09       Impact factor: 2.980

Review 10.  The Netherlands: health system review.

Authors:  Willemijn Schäfer; Madelon Kroneman; Wienke Boerma; Michael van den Berg; Gert Westert; Walter Devillé; Ewout van Ginneken
Journal:  Health Syst Transit       Date:  2010
View more
  1 in total

1.  Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab).

Authors:  Mazin Derzi; Theodore R Johnson; Ahmed M Shoieb; Hugh D Conlon; Penny Sharpe; Andrew Saati; Sarah Koob; Michael W Bolt; Leslie G Lorello; Jim McNally; Carol F Kirchhoff; Teresa A Smolarek; Michael W Leach
Journal:  Adv Ther       Date:  2016-09-01       Impact factor: 3.845
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.